LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-20
Case ID: NM_000249.4_c.1964T_C_20261120_021216
Framework: ACMG/AMP 2015
Variant classification summary

NM_000249.4:c.1964T>C

MLH1  · NP_000240.1:p.(Ile655Thr)  · NM_000249.4
GRCh37: chr3:37090075 T>C  ·  GRCh38: chr3:37048584 T>C
Gene: MLH1 Transcript: NM_000249.4
Final call
Likely Benign
BS3 supporting BP4 supporting
All criteria require review: For research and educational purposes only.
Gene
MLH1
Transcript
NM_000249.4
Protein
NP_000240.1:p.(Ile655Thr)
gnomAD AF
5.5158497011525024e-05 (v4.1)
ClinVar
Likely benign
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
BS3 Supporting: exact-variant assays showed retained repair activity, MLH1 expression, and no detectable splicing abnormality.
2
BP4 Supporting: the exact HCI pathogenicity prior is 0.0077, below the VCEP threshold of 0.11.
Final determination: Under Rule19 of the MLH1 VCEP Version 2.0 framework, at least two Supporting benign criteria are sufficient for a Likely Benign classification; BS3 Supporting and BP4 Supporting meet this rule.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: c.1964T>C is an exon-17 missense SNV, while the governing PVS1 decision-tree path applies to nonsense or frameshift variants predicted to undergo NMD.
cspec vcep_pvs1_decisiontree_mmr pvs1_variant_assessment PMID:17510385 PMID:31332305
PS1 Not met Not met: the VCEP-listed same-residue comparator p.Ile655Phe is Uncertain significance, not the Pathogenic classification required for PS1.
cspec vcep_vcep_pilot_variants_mmr
PS2 Not assessed Not assessed: affected probands were reported, but no parental testing or evidence establishing de novo origin was provided for PS2 point assignment.
cspec PMID:8938136 PMID:10970186
PS3 Not met Not met: I655T retained 73.8% in-vitro mismatch-repair activity and >75% relative MLH1 expression, rather than demonstrating deficient function.
cspec vcep_functional_assay_svi_documentation_mmr vcep_functional_assay_flowchart PMID:17510385
PS4 N/A Not applicable: the MLH1 VCEP explicitly marks PS4 Not Applicable.
cspec
PM1 N/A Not applicable: the MLH1 VCEP explicitly marks PM1 Not Applicable, regardless of residue 655 appearing within a listed interaction-domain interval.
cspec vcep_mmr_functional_domains
PM2 Not met Not met: gnomAD v4.1 total AF is 5.51585e-05, above the VCEP PM2 threshold of 0.00002 (less than 1 in 50,000 alleles).
cspec gnomad_v4 vcep_vcep_pilot_variants_mmr
PM3 Not assessed Not assessed: no documented CMMRD phenotype or phased pathogenic MLH1 variant in trans, and gnomAD v4.1 grpmax FAF 5.3e-05 exceeds the PM2_Supporting threshold of <0.00002.
cspec gnomad_v4 PMID:8938136 PMID:10970186
PM4 N/A Not applicable: the MLH1 VCEP explicitly designates PM4 as Not Applicable, and c.1964T>C is a missense SNV without a protein-length change.
cspec PMID:17510385 PMID:31332305
PM5 Not met Not met: the only VCEP-listed alternate residue-655 missense, p.Ile655Phe, is Uncertain significance rather than Pathogenic.
cspec vcep_vcep_pilot_variants_mmr
PM6 N/A Not applicable: the VCEP marks PM6 as not applicable and directs assumed de novo evidence to its PS2 point system.
cspec
PP1 Not assessed Not assessed: no informative affected-relative genotypes or combined Bayes Likelihood Ratio were reported; the only family entry was explicitly non-informative.
cspec PMID:8938136 PMID:17510385
PP2 N/A Not applicable: the MLH1 VCEP explicitly marks PP2 Not Applicable for this framework.
cspec
PP3 Not met Not met: HCI prior probability is 0.0077, below the PP3 Supporting threshold of >0.68 for missense variants.
cspec vcep_hci_priors_mlh1
PP4 Not assessed Not assessed: two MSI-H colorectal tumors are reported, but MLH1 promoter methylation exclusion required by the VCEP is undocumented.
cspec PMID:10970186 PMID:11376800
PP5 N/A Not applicable: the MLH1 VCEP explicitly marks PP5 Not Applicable.
cspec
BA1 Not met Not met: gnomAD v4.1 Grpmax FAF is 0.000053 (0.0053%), below the VCEP BA1 threshold of 0.001 (0.1%).
cspec gnomad_v4 vcep_vcep_pilot_variants_mmr
BS1 Not met Not met: gnomAD v4.1 Grpmax FAF is 0.000053 (0.0053%), below the VCEP BS1 lower threshold of 0.0001 (0.01%).
cspec gnomad_v4 vcep_vcep_pilot_variants_mmr
BS2 Not assessed Not assessed: no documented in-trans pathogenic MLH1 variant, confirmed phase, qualifying late-onset cancer, or CMMRD assessment is available for the BS2 rule.
cspec vcep_vcep_pilot_variants_mmr
BS3 Met Met at Supporting: I655T showed 73.8% repair activity, >75% MLH1 expression, and no detectable transcript-splicing abnormality in exact-variant assays.
cspec vcep_functional_assay_svi_documentation_mmr vcep_functional_assay_flowchart PMID:17510385 PMID:31332305
BS4 Not assessed Not assessed: no non-segregating affected relatives or combined Bayes Likelihood Ratio below the VCEP thresholds were reported.
cspec
BP1 N/A Not applicable: the MLH1 VCEP explicitly marks BP1 Not Applicable for this framework.
cspec
BP2 N/A Not applicable: the MLH1 VCEP marks BP2 not applicable and directs evaluators to use BS2 instead.
cspec
BP3 N/A Not applicable: the MLH1 VCEP explicitly designates BP3 as Not Applicable, and c.1964T>C is a missense SNV rather than an in-frame deletion in a repeat region.
cspec PMID:17510385 PMID:31332305
BP4 Met Met, Supporting: HCI prior probability is 0.0077, below the VCEP BP4 threshold of <0.11.
cspec vcep_hci_priors_mlh1
BP5 Not assessed Not assessed: reported tumors are MSI-H, whereas BP5 requires qualifying MSS/no-loss tumors or BRAF V600E/MLH1 methylation evidence.
cspec PMID:10970186 PMID:11376800
BP6 N/A Not applicable: the MLH1 VCEP explicitly marks BP6 Not Applicable.
cspec
BP7 N/A Not applicable: c.1964T>C is a coding missense variant, not a synonymous or intronic variant within BP7 scope.
cspec
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.